赛立奇单抗注射液 | China Drugs ListXeligekimab Injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 重庆智翔金泰生物制药股份有限公司Chongqing Genrix Biopharmaceutical Co., Ltd.
- 药品类型
- 生物药Biologic
- 治疗领域
- 皮肤科Dermatology
- 公开来源记录的适应症
- 1. 银屑病:本品用于治疗适合系统治疗或光疗的中度至重度斑块状银屑病成人患者。 2. 强直性脊柱炎 ( 放射学阳性中轴型脊柱关节炎 ) :本品用于常规治疗疗效欠佳的强直性脊柱炎 ( 放射学阳性中轴型脊柱关节炎 ) 成人患者。(1) Psoriasis: for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. (2) Ankylosing spondylitis (radiographic axial spondyloarthritis): for adults with an inadequate response to conventional treatment.
- 适应症来源与口径
- 来源日期： 2025, 2026. 适应症转录自国家医保局公开的企业申报资料；不代表已核实完整的现行说明书。Source date(s): 2025, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。 完整文件为较旧版本；较新适应症由另行公告或申报资料支持。Complete official prescribing information obtained. Mainland China label. The full document is an older version; newer indications are supported by separate announcements or submissions.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限：1.适合系统治疗或光疗的中度至重度斑块状银屑病成人患者；2.常规治疗疗效欠佳的强直性脊柱炎(放射学阳性中轴型脊柱关节炎)成人患者。Limited to: (1) adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy; (2) adults with ankylosing spondylitis (radiographic axial spondyloarthritis) with an inadequate response to conventional treatment.
- 医保期限
- 2026-01-01 至 2027-12-312026-01-01 to 2027-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.